CEVACeva Inc
- Next report
- No date yet
- none in the next 8 weeks
- Last result
- −$0.05
- vs $0.00 expected on Nov 9
- Stock move on it
- −8.65%
- one session
- Price
- $26.27
- −2.49% today · $1.27B cap
Past and upcoming reports
1
| Nov 9, 2026 | Sep 30, 2026 | Before the market opens | $0.00 | −$0.05 | −8.65% |
After the report
Nov 9, 2026 report
CEVA’s AI narrative met a reported $0.05 EPS shortfall. valuation now depends on fourth-quarter revenue delivery.
CEVA reported third-quarter EPS of -$0.05 versus a $0.00 estimate on November 9. Guidance details were unavailable, while the stock rose 10.27% to $26.96 on November 11. AI licensing remained the positive narrative, but weak near-term earnings execution and a forward P/E of 51.4 create a high bar for fourth-quarter revenue delivery.
Reported against expected
CEVA reported EPS of -$0.05 for the quarter ended September 30, versus a $0.00 estimate, a $0.05 shortfall. the percentage surprise was unavailable.
Guidance
Specific management guidance was unavailable. the identified forward catalyst was fourth-quarter revenue delivery.
How the stock reacted
The stock rose $2.51, or 10.27%, to $26.96 on November 11, with 543,191 shares traded. event-day and subsequent reaction-window percentages were unavailable.
What changed
Reported EPS was -$0.05 versus a $0.00 estimate, while fourth-quarter revenue delivery became the key forward catalyst.
What the price now assumes
The November 11 gain to $26.96 suggests investors emphasized AI licensing potential despite the reported loss.
What it means for the business
Maintain a cautious growth bias. upgrade only if fourth-quarter revenue delivery validates AI momentum without another earnings shortfall.
The next one to three months, as we saw it then
Better case30%
AI licensing converts into fourth-quarter revenue delivery, improving confidence that projected EPS growth can offset the reported loss.
Base case45%
AI momentum remains credible, but weak profitability and a 51.4 forward P/E keep the shares sensitive to execution evidence.
Worse case25%
Another execution miss exposes valuation risk, with operating margin already -11.5% and forward P/E at 51.4 versus a 17.3 sector average.
If you hold it
Hold unless next-quarter revenue misses guidance materially or customer concentration risk worsens.
If you are watching
Enter only after fourth-quarter revenue delivery validates AI licensing without another earnings shortfall. no trade if guidance remains unavailable or execution weakens.
Scenario odds are a judgement, not measured.